From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

Promising Alzheimer’s study data sends Bioarctic stock soaring

The drug candidate lecanemab from Swedish company Bioarctic significantly slowed down the deterioration in patients with early on-set Alzheimer’s, according to ...

Elicera develops CAR-T against solid tumours – may become the first in the world

Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work agains...

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct s...

Life Science Sweden´s international issue is on its way

A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.

CTC Clinical Trial Consultants AB

”We need compatibility“

Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on ef...

Scale Up Your Image Analysis

ZEISS arivis Hub for accelerated analysis and faster results.

Danska life science-industrin står för rekordhög export

Den danska exporten av life science-produkter har ökat explosionsartat, med en tillväxt på 227 procent sedan 2008 och utgjorde 2023 så mycket som 19 procent av ...

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Smart "trial and error" för snabbare innovation

För att bli och förbli konkurrenskraftiga måste dagens företag och organisationer innovera i allt snabbare takt.

The Swedish government is to increase its investment in cancer care

The Swedish government wants to invest more in cancer and paediatric cancer care and proposes to allocate SEK 500 million per year for this purpose in the coming years.

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

The art of building a biologic drug

The first biosimilar from Xbrane Biopharma was launched earlier this year, and several more are under development at the company’s facility in Solna, Sweden. “W...

Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”

In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 1...

”Information security must become part of the Swedish life science strategy”

Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.

How Volume EM Advances Life Science Research

Free webinar series.

A modular system for precise and automated cell dispensing

How the benefits of laboratory automation can be combined with gentle cell handling.

He will be the new chair of Medicon Valley Alliance

Niels Abel Bonde is the nomination committee’s proposal and the most likely person to take over as the new chairman of the Swedish-Danish life science cluster o...

Microscope and measuring machine in one

ZEISS O-INSPECT duo covers two essential applications in quality assurance.

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.